CRISPR Therapeutics AG Statistics
Share Statistics
CRISPR Therapeutics AG has 85.35M shares outstanding. The number of shares has increased by 1.38% in one year.
| Shares Outstanding | 85.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 81.68M |
| Failed to Deliver (FTD) Shares | 687 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 18.12M, so 21.23% of the outstanding shares have been sold short.
| Short Interest | 18.12M |
| Short % of Shares Out | 21.23% |
| Short % of Float | 22.18% |
| Short Ratio (days to cover) | 9.52 |
Valuation Ratios
The PE ratio is -32.28 and the forward PE ratio is -10.07.
| PE Ratio | -32.28 |
| Forward PE | -10.07 |
| PS Ratio | 13.36 |
| Forward PS | 6.2 |
| PB Ratio | 2.63 |
| P/FCF Ratio | -18.21 |
| PEG Ratio | n/a |
Enterprise Valuation
CRISPR Therapeutics AG has an Enterprise Value (EV) of 4.81B.
| EV / Earnings | -31.3 |
| EV / Sales | 12.95 |
| EV / EBITDA | -23.72 |
| EV / EBIT | -21.61 |
| EV / FCF | -17.66 |
Financial Position
The company has a current ratio of 17.54, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.54 |
| Quick Ratio | 17.54 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.46 |
| Cash Flow / Debt | -9.3 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.08% and return on capital (ROIC) is -10.69%.
| Return on Equity (ROE) | -0.08% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -10.69% |
| Revenue Per Employee | 912.05K |
| Profits Per Employee | -377.42K |
| Employee Count | 407 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 2.89M |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -39.56% in the last 52 weeks. The beta is 1.66, so CRISPR Therapeutics AG's price volatility has been higher than the market average.
| Beta | 1.66 |
| 52-Week Price Change | -39.56% |
| 50-Day Moving Average | 46.21 |
| 200-Day Moving Average | 51.53 |
| Relative Strength Index (RSI) | 34.93 |
| Average Volume (20 Days) | 1.75M |
Income Statement
In the last 12 months, CRISPR Therapeutics AG had revenue of 371.21M and earned -153.61M in profits. Earnings per share was -1.94.
| Revenue | 371.21M |
| Gross Profit | 240.96M |
| Operating Income | -222.54M |
| Net Income | -153.61M |
| EBITDA | -202.70M |
| EBIT | -222.54M |
| Earnings Per Share (EPS) | -1.94 |
Balance Sheet
The company has 389.48M in cash and 238.63M in debt, giving a net cash position of 150.84M.
| Cash & Cash Equivalents | 389.48M |
| Total Debt | 238.63M |
| Net Cash | 150.84M |
| Retained Earnings | -999.70M |
| Total Assets | 2.26B |
| Working Capital | 1.85B |
Cash Flow
In the last 12 months, operating cash flow was -260.38M and capital expenditures -11.97M, giving a free cash flow of -272.35M.
| Operating Cash Flow | -260.38M |
| Capital Expenditures | -11.97M |
| Free Cash Flow | -272.35M |
| FCF Per Share | -3.44 |
Margins
Gross margin is 64.91%, with operating and profit margins of -59.95% and -41.38%.
| Gross Margin | 64.91% |
| Operating Margin | -59.95% |
| Pretax Margin | -40.6% |
| Profit Margin | -41.38% |
| EBITDA Margin | -54.61% |
| EBIT Margin | -59.95% |
| FCF Margin | -73.37% |
Dividends & Yields
CRSP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.06% |
| FCF Yield | -8.32% |
Analyst Forecast
The average price target for CRSP is $84, which is 119.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $84 |
| Price Target Difference | 119.1% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | 6.63 |
| Piotroski F-Score | 3 |